Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A L Harris

Showing results (71-80 of 682) with videos related to

Pageof 69
Sort By:
Biochemical Pharmacology|June 1, 1988
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cellsN J Curtin, A L Harris
Journal of Mammary Gland Biology and Neoplasia|April 1, 1997
The epidermal growth factor receptor in breast cancerS B Fox, A L Harris
British Journal of Haematology|July 11, 2000
Current status of antiangiogenic factorsK L Talks, A L Harris
Provider (Washington, D.C.)|February 28, 2001
Give CNAs a career ladder to climbA L Harris, G M Maier
British Journal of Haematology|October 1, 1993
The role of DNA topoisomerases II in drug resistanceP A Alton, A L Harris
The Journal of Biological Chemistry|January 28, 1999
Regulation of connexin channels by pH. Direct action of the protonated form of taurine and other aminosulfonatesC G Bevans, A L Harris
Lancet (London, England)|March 30, 1985
Ifosfamide/mesa and encephalopathyB M Cantwell, A L Harris
Investigational New Drugs|January 1, 1997
Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapyS B Fox, A L Harris
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
Clinical prognostic significance of tumour angiogenesisP S Craft, A L Harris
Expert Opinion on Investigational Drugs|July 5, 2005
Anti-angiogenic therapies in cancer clinical trialsH T Zhang, A L Harris
Pageof 69

Showing results (71-80 of 682) with videos related to

Sort By:
Pageof 69
Biochemical Pharmacology|June 1, 1988
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cellsN J Curtin, A L Harris
Journal of Mammary Gland Biology and Neoplasia|April 1, 1997
The epidermal growth factor receptor in breast cancerS B Fox, A L Harris
British Journal of Haematology|July 11, 2000
Current status of antiangiogenic factorsK L Talks, A L Harris
Provider (Washington, D.C.)|February 28, 2001
Give CNAs a career ladder to climbA L Harris, G M Maier
British Journal of Haematology|October 1, 1993
The role of DNA topoisomerases II in drug resistanceP A Alton, A L Harris
The Journal of Biological Chemistry|January 28, 1999
Regulation of connexin channels by pH. Direct action of the protonated form of taurine and other aminosulfonatesC G Bevans, A L Harris
Lancet (London, England)|March 30, 1985
Ifosfamide/mesa and encephalopathyB M Cantwell, A L Harris
Investigational New Drugs|January 1, 1997
Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapyS B Fox, A L Harris
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
Clinical prognostic significance of tumour angiogenesisP S Craft, A L Harris
Expert Opinion on Investigational Drugs|July 5, 2005
Anti-angiogenic therapies in cancer clinical trialsH T Zhang, A L Harris
Pageof 69